Profile data is unavailable for this security.
About the company
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
- Revenue in USD (TTM)0.00
- Net income in USD-35.58m
- Incorporated2015
- Employees14.00
- LocationIterum Therapeutics PLCFitzwilliam Court1st Floor, Leeson Close, Dublin 2DUBLIN D02 YW24IrelandIRL
- Phone+353 16694820
- Websitehttps://www.iterumtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GlycoMimetics Inc | 10.00k | -37.28m | 19.64m | 35.00 | -- | 0.679 | -- | 1,963.59 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Goldenwell Biotech Inc | 1.08k | -114.27k | 19.80m | -- | -- | 368.37 | -- | 18,333.33 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 19.86m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
Vincerx Pharma Inc | 0.00 | -38.25m | 20.08m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
Singular Genomics Systems Inc | 2.49m | -96.21m | 20.30m | 255.00 | -- | 0.1295 | -- | 8.15 | -39.39 | -39.39 | 1.02 | 63.47 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
VBI Vaccines Inc | 9.41m | -83.99m | 20.94m | 131.00 | -- | -- | -- | 2.22 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
Oncternal Therapeutics Inc | 1.15m | -36.38m | 20.95m | 27.00 | -- | 0.9141 | -- | 18.21 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
Bioxytran Inc | 0.00 | -4.30m | 21.00m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 21.04m | 4.00 | -- | 3.09 | -- | 323.68 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
Forte Biosciences Inc | 0.00 | -32.14m | 21.14m | 11.00 | -- | 0.7359 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Iterum Therapeutics PLC | 0.00 | -35.58m | 21.36m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Aprea Therapeutics Inc | 963.81k | -12.72m | 21.67m | 7.00 | -- | 0.7491 | -- | 22.48 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Viracta Therapeutics Inc | 0.00 | -47.99m | 21.84m | 40.00 | -- | 3.88 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
Gain Therapeutics Inc | 0.00 | -21.14m | 22.93m | 29.00 | -- | 2.65 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Cocrystal Pharma Inc | 0.00 | -16.75m | 22.99m | 12.00 | -- | 1.02 | -- | -- | -1.65 | -1.65 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -52.03 | -50.94 | -56.92 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
Yubo International Biotech Ltd | 455.72k | -1.26m | 22.99m | 18.00 | -- | -- | -- | 50.46 | -0.0105 | -0.0105 | 0.0038 | -0.0172 | 0.2488 | 0.4126 | 5.27 | 25,317.78 | -70.32 | -- | -- | -- | 80.24 | -- | -282.61 | -- | 0.1487 | -4,023.75 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Point72 Asset Management LPas of 31 Mar 2024 | 434.00k | 2.62% |
APOLLON FINANCIAL LLCas of 30 Jun 2024 | 224.75k | 1.36% |
Renaissance Technologies LLCas of 31 Mar 2024 | 110.33k | 0.67% |
Millennium Management LLCas of 31 Mar 2024 | 28.04k | 0.17% |
Bank Vontobel AGas of 31 Mar 2024 | 15.00k | 0.09% |
UBS Securities LLCas of 31 Mar 2024 | 12.02k | 0.07% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 5.48k | 0.03% |
Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 1.20k | 0.01% |
Tower Research Capital LLCas of 31 Mar 2024 | 468.00 | 0.00% |
RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 100.00 | 0.00% |